4 FTSE 100 stars offering unmissable value! GlaxoSmithKline plc, Royal Mail plc, GKN plc and BAE Systems plc

Royston Wild explains why FTSE 100 (INDEXFTSE: UKX) stars GlaxoSmithKline plc (LON: GSK), Royal Mail plc (LON: RMG), GKN plc (LON: GKN) and BAE Systems plc (LON: BA) are ‘must have’ stocks for bargain hunters.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m looking at four FTSE 100 (INDEXFTSE: UKX) plays dealing at ridiculous prices!

Post a fortune

I’m convinced that exploding online shopping activity bodes well for Britain’s oldest courier Royal Mail (LSE: RMG), as it’s a phenomenon that should keep blasting parcel volumes higher at home and across the continent.

The City expects earnings at Royal Mail to dip 5% in the year to March 2017 as the impact of huge restructuring weighs. Still, this leaves the business dealing on a terrific P/E rating of 12.6 times. And this reading slips to 12.5 times for 2018 thanks to a predicted 3% earnings advance.

And dividend seekers should be interested in estimated rewards of 23p and 24p per share for 2017 and 2018, respectively, figures that yield 4.3% and 4.5%.

Engineer a fortune

Investor appetite for GKN (LSE: GKN) has been numbed in recent times by weakening demand for its agricultural and aerospace products. However, I’m convinced the long-term outlook for the engineer’s critical marketplaces remains solid, particularly at the firm’s GKN Driveline car division.

Consequently a P/E rating of 9.7 times for 2016 is exceptional value, in my opinion, despite an anticipated 1% drop for the current period. Indeed, GKN’s growth story is anticipated to get back on track from 2017, when an anticipated 8% bottom-line advance pushes the multiple to just 9.1 times.

Meanwhile, predicted dividends of 9.1p and 9.6p per share for this year and next yield a handy 3.3% and 3.5%, respectively.

Defence darling

With Western defence budgets heading back in the right direction, I believe the earnings picture at BAE Systems (LSE: BA) is in great shape. On top of this, the arms builder is also enjoying rising demand from non-US and UK customers, and I expect this to keep rising along with galloping wealth levels in these hot new regions.

BAE Systems is expected to endure a 4% earnings dip in 2016 due to near-term contract timing issues. But a 7% rebound is predicted for 2017. As a consequence BAE Systems deals on decent P/E ratios of 12.3 times and 11.6 times for these years.

And anticipated dividends of 21.4p per share for 2016 and 22p for next year yield a handsome 4.4% and 4.6%, respectively.

Medicines marvel

Although a battered growth pick in recent times, I believe that GlaxoSmithKline’s (LSE: GSK) efforts to rejuvenate its product pipeline should get earnings firing again from this year onwards, and put an end to the enduring impact of patent losses on revenues expansion.

This view is shared by the City, and the bottom line is expected to advance 16% this year and 4% in 2017. These figures leave GlaxoSmithKline dealing on reasonable P/E ratings of 16.3 times and 15.8 times for these years.

But it’s in the dividend stakes where the pharma giant really sets itself apart, with a planned 80p-per-share dividend for this year and next yielding a smashing 5.4%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK owns shares of GKN. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »